iShares Nasdaq Biotechnology (IBB)

Add to Watchlists
Create an Alert
365.00 +1.40  +0.39% NASDAQ May 22, 10:32AM Delayed 2m USD
View Full Chart
IBB Price Chart

IBB Description

iShares Nasdaq Biotechnology is a long only equity fund managed by iShares that tracks the NASDAQ Biotechnology TR USD index and has 8.926B USD assets under management. It has an expected distribution yield of 0.12%, a Forecasted PE Ratio of 24.77, and a Forecasted Price to Book Value of 6.339. The fund has a net expense ratio of 0.48%, turns over its positions 39.00% per year, and is traded on the NASDAQ.

IBB Key Info

Expense Ratio (7-31-14) 0.48%
Assets Under Management (5-21-15) 8.926B
30-Day Average Volume (5-21-15) 1.715M
Net Asset Value (5-20-15) 363.46
Discount or Premium to NAV (5-20-15) 0.04%
Turnover Ratio (3-31-14) 39.00%

IBB Asset Allocation

Type % Net % Long % Short
Cash 0.00% 0.00% 0.00%
Stock 99.95% 99.95% 0.00%
Bond 0.00% 0.00% 0.00%
Convertible 0.00% 0.00% 0.00%
Preferred 0.00% 0.00% 0.00%
Other 0.05% 0.05% 0.00%
As of May 19, 2015

IBB Region Exposure

Americas 95.91%
North America 95.91%
Latin America 0.00%
Greater Europe 4.04%
United Kingdom 1.99%
Europe Developed 2.01%
Europe Emerging 0.00%
Africa/Middle East 0.05%
Greater Asia 0.05%
Japan 0.00%
Australasia 0.00%
Asia Developed 0.00%
Asia Emerging 0.05%
Market Classification
% Developed Markets 99.95%
% Emerging Markets 0.05%
As of May 19, 2015
Region breakdown data is calculated by using the long position holdings of the portfolio.

IBB Stock Sector Exposure

Basic Materials 0.00%
Communication Services 0.00%
Consumer Cyclical 0.00%
Consumer Defensive 0.00%
Energy 0.00%
Financial Services 0.00%
Healthcare 100.0%
Industrials 0.00%
Real Estate 0.00%
Technology 0.00%
Utilities 0.00%
As of May 19, 2015

IBB Stock Market Capitalization

Giant 33.12%
Large 27.35%
Medium 18.02%
Small 13.63%
Micro 7.82%
As of May 19, 2015
View More Holdings

IBB Top 10 Holdings

Name % Weight Price Chg %
Gilead Sciences Inc 8.30% 112.21 +0.89%
Amgen Inc 8.06% 164.15 +0.19%
Biogen Inc 7.50% 400.21 -0.23%
Celgene Corp 7.47% 116.30 +0.09%
Regeneron Pharmaceuticals Inc 7.21% 516.57 +0.11%
Mylan NV 5.14% 70.16 +0.31%
Vertex Pharmaceuticals Inc 4.18% 125.00 -0.04%
Illumina Inc 4.02% 204.68 +0.77%
Alexion Pharmaceuticals Inc 3.49% 170.00 +0.85%
Biomarin Pharmaceutical Inc 2.92% 126.64 -0.19%
As of May 19, 2015
Advertisement

IBB Basic Info

Style
Broad Asset Class Sector Equity
Broad Category Equity
Prospectus Objective Specialty - Health
Fund Owner Firm Name iShares
Benchmark Index
NASDAQ Biotechnology TR USD 100.0%
Key Dates
Inception Date 2/5/2001
Last Annual Report Date 3/31/2014
Last Prospectus Date 7/31/2014
Attributes
Exchange Traded Share Yes
Exchange Traded Note No
Enhanced Index Fund No
Index Fund Yes
Inverse Fund No
Leveraged Fund No
Fund of Funds No
Currency Hedged Fund No
Synthetic Replication Fund No
Has Dividend Investment Plan Yes
General Availability
Available for Insurance Product No
Available for Retirement Plan No
Available RRSP No

IBB Manager Info

Name Tenure
Diane Hsiung 7.25 yrs
Greg Savage 7.25 yrs
Jennifer Hsui 2.67 yrs
Matthew Goff 1.51 yrs

IBB Risk Info

Beta 0.9095
30 Day Average Volatility 23.76%

IBB Fundamentals

Dividend Yield TTM (5-22-15) 0.12%
Weighted Average PE Ratio 27.50
Weighted Average Price to Sales Ratio 9.140
Weighted Average Price to Book Ratio 8.081
Weighted Median ROE 11.75%
Weighted Median ROA 2.60%
Forecasted Dividend Yield 0.22%
Forecasted PE Ratio 24.77
Forecasted Price to Sales Ratio 6.566
Forecasted Price to Book Ratio 6.339
Number of Holdings 147
As of May 19, 2015

IBB Growth Estimates

Forecasted 5 Yr Earnings Growth 13.17%
Forecasted Book Value Growth 16.18%
Forecasted Cash Flow Growth 34.27%
Forecasted Earnings Growth 37.19%
Forecasted Revenue Growth 17.20%
As of May 19, 2015

IBB Performance

  Returns Total Returns
1M 0.14% 0.14%
3M 8.49% 8.49%
6M 23.72% 23.72%
1Y 58.88% 59.15%
3Y 195.0% 197.0%
5Y 352.0% 357.9%
As of May 20, 2015

IBB Flows

1M -89.34M
3M 511.99M
6M 1.049B
YTD 473.99M
1Y 1.228B
3Y 2.323B
5Y 2.251B
As of April 30, 2015
Advertisement

You've hit the 10 page limit on YCharts.

Experience the power of YCharts.
Start your Free 7-Day Trial.

Start My Free Trial No credit card required.

Already a subscriber? Sign in.

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}
Start your free 7-Day Trial.

{{root.upsell.info.button_text}} No credit card required.

Already a subscriber? Sign in.